

Zeitschrift: Acta Tropica
Herausgeber: Schweizerisches Tropeninstitut (Basel)
Band: 41 (1984)
Heft: 1

Artikel: Albendazole : a new single dose anthelmintic : study in 1455 patients
Autor: Coulaud, J.P. / Rossignol, J.F.
DOI: <https://doi.org/10.5169/seals-313281>

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. [Mehr erfahren](#)

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. [En savoir plus](#)

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. [Find out more](#)

Download PDF: 29.03.2026

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

¹ Institut de Médecine et d'Epidémiologie Tropicales, Paris, France

² Department of Internal Medicine, University of South Alabama, College of Medicine, Mobile, Alabama 36688, USA

Albendazole: a new single dose anthelmintic

Study in 1455 patients

J. P. COULAUD¹, J. F. ROSSIGNOL²


Summary

Albendazole has been tested in an open trial conducted in France, seven countries of West-Africa, Martinique and the People's Republic of China in a total of 1455 patients harboring single or mixed infections caused by roundworms, pinworms, hookworms and whipworms. All patients were closely observed before and after treatment for clinical side effects and hematology and clinical chemistry values were done in about 5% of the cases. Fecal samples obtained before and approximately 15, 16 and 17 days after treatment were examined using the Kato test, and when negative, a concentration technic. In case of ancylostomiasis, a coproculture was carried out for species identification. Following a single oral dose, albendazole was highly effective in enterobiasis (100%), ascariasis (89%), ancylostomiasis caused by *Necator americanus* (88%) and trichuriasis (70%). The drug did not procedure any significant adverse reactions or modifications of the hematological and clinical blood chemistry values and only 6% of the 1455 patients reported minor side effects.

Key words: albendazole; roundworms; side effects.

Introduction

Albendazole is methyl-5 propylthio-1-H benzimidazol-2-yl carbamate with the following structural formula:



Correspondence: Prof. J. P. Coulaud, Institut de Médecine et d'Epidémiologie Tropicales, Hôpital Claude Bernard, 10, Avenue Porte d'Aubervilliers, F-75019 Paris, France

Table 1. Number, age and sex of patients

Age (years)	Males	Females	Total
2-12	225	237	462
13-19	231	133	364
20-29	183	81	264
30-39	129	73	202
40-49	56	36	92
More than 49	47	24	71
Total	871	584	1455

It has been reported to be a safe and effective broad spectrum nematocidal drug in the treatment of ascariasis, ancylostomiasis caused by *Necator americanus* and *Ancylostoma duodenale*, trichuriasis and strongyloidiasis (Pene et al., 1982). The objective of this multicenter open clinical trial was to confirm the effectiveness of a single 400 mg dose against the major intestinal nematodes.

Patients, Material and Methods

Sites. The study was conducted in Paris, France, in Martinique, in seven countries of West-Africa: Mali, Senegal, Niger, Guinea, Ivory Coast, Cameroon and Central African Republic, and in two provinces of the People's Republic of China: Inner Mongolia and Xinjiang.

Patients. A total of 1455 patients, mainly black African, and some 171 Chinese harboring a broad spectrum of nematodes was included. They remained outpatients of hospitals or dispensaries throughout the course of the study. Those patients who were receiving or who had received anthelmintics for 7 days prior to initiation of the study were excluded, as well as those with an acute illness (with or without fever), pregnant females, nursing mothers, children under three years, epilepsy cases and those with generalized active skin conditions. In general, patients who experienced high sensitivity to any drug or those receiving long-term therapy or those having chronic illnesses or proteinuria were excluded. Among 1455 patients, 871 were males and 584 females. There were 462 children under 12 years old, 225 boys and 237 girls. Number, age and sex distribution is shown in Table 1.

Methods. Each patient underwent a complete physical examination, including a fecal examination on a single stool specimen using the Kato technique (Kato and Miura, 1954; Katz et al. 1972). A Graham scotch test was also performed for suspected pinworm infections. In case of ancylostomiasis, a coproculture using the Harada-Mori technique (WHO, 1963) was carried out for species identification. At the same time, a pregnancy test was performed in all females of child-bearing potential and in 75 patients, haematology (CBC) and clinical chemistry values (BUN, SGOT, SGPT, proteinuria, glycosuria) were also obtained.

Albendazole was made available as a 200 mg tablet or 2% suspension. Treatments were administered as a single 400 mg dose (2 tablets or 20 ml of suspension) in the presence of the physician and the mouth was inspected after dosing. No fasting was required.

The same physical examination was carried out 24 to 72 hours after treatment and each patient was carefully questioned about clinical side effects and again in the 75 patient group, haematological and clinical chemistry values were determined.

Cure rate was based on repeated fecal examinations using the Kato technique and a concentration technique (Junod) when Kato was found negative. They were generally conducted on days

Table 2. Efficacy of albendazole treatment

Parasite	No. of cases	Mean egg count (eggs/g feces)	Cure rate	Mean egg reduction Non-cured patients
<i>E. vermicularis</i>	141	—	100%	—
<i>A. lumbricoides</i>	502	2527	92%	99%
<i>N. americanus</i>	743	612	90%	98%
<i>T. trichiura</i>	430	590	70%	99%

Table 3. Albendazole efficacy per intensity of infection

Egg count class	No. of cases**	Mean egg count (egg/g feces)	% cured	Mean egg reduction
<i>A. lumbricoides</i>				
Light infections*	276	521	96.3	38.4
Moderate infections*	206	3,655	84.9	80.2
Heavy infections*	20	51,839	100.0	—
<i>N. americanus</i>				
Light infections*	694	330	91.3	71.8
Moderate infections*	46	3,902	70.0	66.3
Heavy infections*	3	15,338	67.0	64.0
<i>T. trichiura</i>				
Light infections*	390	367	73.0	81.2
Moderate infections*	39	2,839	46.1	71.2

* *Light infections*: less than 2,000 eggs per gram of feces. *Moderate infections*: from 2,000 to 10,000 eggs per gram of feces. *Heavy infections*: more than 10,000 eggs per gram of feces

** Multiple infections included

Table 4. Side effects of albendazole treatment

Clinical signs	Number of cases
Epigastric pains	33 (2.2%)
Nausea	4 (0.2%)
Headache	16 (1.0%)
Vomiting	1 (0.1%)
Dizziness	2 (0.1%)
Diarrhea	29 (1.9%)
Constipation	1 (0.1%)
Pruritus ani	1 (0.1%)
Dry mouth	1 (0.1%)
Total	88 (6.0%)

15, 16 and 17 after treatment and three negative fecal examinations were necessary to consider the patient cured. In cases of diagnosed enterobiasis, a Graham scotch test was also done on the same days.

Results

Out of 1455 patients, 1104 (75.8%) had single infections, 283 (19.4%) had mixed infections involving two parasites, 67 (4.6%) had three parasites, and only one four different organisms.

The drug was highly effective against *Ascaris lumbricoides*, *Enterobius vermicularis*, *Necator americanus* and *Trichuris trichiura* (Table 2).

In 28 patients harboring the cestode *Hymenolepis nana*, a cure rate of only 42% was recorded following the single 400 mg dose. Eleven patients had *Taenia saginata* and were followed up for only a maximum of 3 weeks. Twenty-one days is generally considered as inadequate to evaluate cure in such an indication. *Strongyloides stercoralis* was only found in 5 cases, an insufficient number for evaluation.

Albendazole efficacy per intensity of infection for each parasite is shown in Table 3.

A total of 88 clinical side effects were reported by the 1455 patients (Table 4). These side effects, observed in 6% of the patients, were minimal and generally disappeared within 48 hours. Haematology and clinical chemistry values obtained from 75 patients before and after treatment always remained within the normal limits.

Discussion and Conclusions

The results of this multi-center open trial conducted in a large number of patients (1455) are very consistent with those reported in our previous experiment carried out against a placebo (Pene et al., 1982). The drug administered as a single 400 mg dose both in adults and children is extremely well tolerated and highly effective against the four major species of intestinal nematodes: pinworms, roundworms, hookworms and whipworms. These results are suggesting that mass treatment could be considered for evaluating the drug in the control of intestinal nematode infections.

Kato K., Miura M.: Comparative examination. Jap. J. Parasit. 3, 35 (1954).

Katz N., Chaves A., Pellegrino J.: A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev. Inst. Med. trop. S. Paulo 14, 397-400 (1972).

Pene P., Monjon M., Garin J. P., Coulaud J. P., Rossignol J. F.: Albendazole a new broad spectrum anthelmintic. Double-blind multicenter clinical trial. Amer. J. trop. Med. Hyg. 31, 263-266 (1982).

World Health Organization: CCTA/WHO African Conference on Ancylostomiasis, Brazzaville, 22-29 August 1961. WHO Techn. Rep. Ser. No. 255 (1963).